Let’s work together
A patient-led opportunity in thyroid treatment.
"A simple problem. A global patient group. A better way forward."
ThyX is building a slow-release thyroxine implant concept for people who manage thyroid treatment every day.
A daily treatment category with global scale.
An estimated 200 million people worldwide live with thyroid conditions. Many rely on daily hormone treatment as part of long-term care.
ThyX is focused on a clear patient need: reducing the everyday friction of medication timing, routine and long-term management.
A simple concept with a clear purpose.
ThyX is being developed as a medical device pathway centred on slow-release thyroxine delivery and patient-led treatment design.
Patient need
A real daily routine that millions of people understand immediately.
Long-acting approach
Aiming to reduce reliance on daily medication planning through slow-release delivery.
Research pathway
Built carefully through development, testing and credible collaboration.
Built from lived experience, not market theory.
ThyX is led by founder Aneta Nash, whose lived experience with thyroid treatment keeps the patient reality at the centre of the company.
The opportunity is commercial, but the reason is human: create a treatment approach that better fits the way people actually live.
"The patient problem is easy to understand because it shows up every day."
— ThyX investor focus
Speak with us about what comes next.
Register your interest to learn more about the development pathway, vision and commercial opportunity behind ThyX.